Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,America ,Robertj Deluccia , ,Data Monitoring Committee ,Company Ph ,Nasdaq ,Society Or Healthcare Epidemiology Of America ,Acurx Pharmaceuticals Inc ,Exchange Commission ,Trial Oversight Committee ,World Antimicrobial Resistance Congress ,Exchange Commission On Form ,Drug Administration ,Acurx Pharmaceuticals ,Prnewswire Acurx Pharmaceuticals Inc ,World Antimicrobial Resistance Scientific Congress On ,Infectious Diseases Society Of America ,Interim Analysis ,Independent Data Monitoring ,Lead Optimization ,Acute Bacterial Skin ,Skin Structure Infections ,Acurx Executive Chairman ,Innovation Showcase ,Independent Data Monitoring Committee ,Gram Positive Selective Spectrum ,Investigational New Drug Application ,Qualified Infectious Disease Product ,Generating New Antibiotic Incentives Now ,World Antimicrobial Resistance ,Antimicrobial Resistance ,Clinical Practice Guidelines ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,Bile Acid ,Ibezapolstat Phase ,Scientific Advisory Board ,Private Securities Litigation Reform Act ,Nc ,